today's Pick
Ebola vaccine trials being fast-tracked: researchers
Publish Date: Aug 28, 2014
Ebola vaccine trials being fast-tracked: researchers
Nigeria warns against complacency in Ebola fight A man reads a poster raising awareness on the Ebola virus reading "the risk of Ebola is still there. Let us apply the protective measures together" in Abidjian, Ivory Coast
  • mail
  • img
newvision

Safety trials on an Ebola vaccine are being fast-tracked, meaning it could be given to healthy volunteers as early as September, researchers said Thursday.

The vaccine will be given to volunteers in Britain, the Gambia and Mali in a bid to tackle the spread of an epidemic which has spread across west Africa, killing 1,552 so far.

Researchers hope the trials could finish by the end of 2014.

If they are successful, the vaccine could then be given to people infected with Ebola, which is spread through bodily fluids.

The move was announced by pharmaceuticals giant GlaxoSmithKline -- which is developing the vaccine with the US National Institutes of Health (NIH) -- and London-based medical charity Wellcome Trust, which is contributing to a grant to pay for the trials.

"A candidate Ebola vaccine could be given to healthy volunteers in the UK, the Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines," the statement said.

A total of 3,062 cases have so far been reported but the World Health Organization warned Thursday that the caseload could eventually exceed 20,000.

The trials, which still need ethical and regulatory approval, will be funded by a £2.8 million (3.5 million euro, $4.6 million) grant from the Wellcome Trust, Britain's Medical Research Council (MRC) and the UK Department for International Development (DFID).

The Oxford study will involve 60 healthy volunteers, while those in the Gambia and Mali will each involve 40.

This will also allow GSK to make some 10,000 extra doses of the vaccine so that if the trials are successful, it could be made available to the WHO quickly.

Safety tests of the vaccine will take place at Oxford University alongside a US trial run by the National Institute of Allergy and Infectious Diseases. AFP  (NIAID). AFP

The statements, comments, or opinions expressed through the use of New Vision Online are those of their respective authors, who are solely responsible for them, and do not necessarily represent the views held by the staff and management of New Vision Online.

New Vision Online reserves the right to moderate, publish or delete a post without warning or consultation with the author.Find out why we moderate comments. For any questions please contact digital@newvision.co.ug

  • mail
  • img
blog comments powered by Disqus
Also In This Section
40,000 children die of diarrhoea, pneumonia annually
Over 40,000 children die every year from diarrhoea and pneumonia, accounting for 25% of all deaths among children....
Grateful to US, Syrian Kurds name baby
Sultan Muslim, a Syrian Kurd, had no doubt what to name her seventh child when he was born, safely in Turkey....
Museveni responds to Ssemogerere interview
President Yoweri Kaguta Museveni has responded to various issues raised by former Democratic Party president Paul Ssemogerere’s in an interview with the Sunday Monitor of September 28....
Hundreds of thousands of Ebola vaccine doses could be rolled out to West Africa by mid-2015, the World Health Organization said Friday, after a new case of the virus was reported in New York and a two-year-old girl died in the first case in Mali....
Museveni directs Makerere on accurate fees structure
President Yoweri Museveni has given the Makerere University leadership up to the end of this month to furnish him with the unit cost of educating each student, with the purpose of establishing an accurate fees structure for the institution....
OPM officials refund scam cash
A number of officials from the Office of the Prime Minister implicated in the multibillion financial scam have refunded....
Should diplomatic passports issued to ex-govt workers be with drawn?
Yes
No
Can't Say
follow us
subscribe to our news letter